ClinicalTrials.gg
RecruitingNCT07157787AUTUMNUpdated Jun 18, 2026

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

A Phase 2 interventional study of ALXN1920 and Placebo in Primary Membranous Nephropathy, sponsored by Alexion Pharmaceuticals, Inc.. Recruiting at 40 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).

02

Conditions studied

  • Primary Membranous Nephropathy

Keywords

  • Primary Membranous Nephropathy
  • PMN
  • ALXN1920
03

In context

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

This study's planned enrollment of 30 is below the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.

Browse Glomerulonephritis, Membranous studies →

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have a documented diagnosis of PMN, established by positive antiPLA2R antibody level (> 20 RU/mL) at Screening, which must be confirmed by a central laboratory
  • Participants are willing to receive the background Standard of Care (SoC)
  • Participants at high risk for disease progression, defined as:

    1. Receiving ACE inhibitor or ARB for a minimum of 8 weeks prior to Screening, with the dose titrated to the maximally tolerated level. Participants with less than 8 weeks on ACE inhibitor or ARB before Screening or who have not yet reached maximally tolerated dose will enter the Run-in Period.
    2. Participants who are on ACE inhibitor or ARB for a minimum of 8 weeks with Systolic Blood Pressure \< 140 mmHg in ≥ 75% of the readings within last 8 weeks.
    3. Having two proteinuria measurements with each > 3.5 g/day, the second measurement showing ≤50% decrease from the first measurement.
  • eGFR60 mL/min/1.73 m2 during Screening calculated by 2021 creatinine formula
  • All participants must receive prophylactic treatment with appropriate antibiotics while receiving Rituximab (RTX), and be willing to be vaccinated against Neisseria meningitidis

Exclusion criteria

Exclusion Criteria:

  • Documented rapid deterioration of kidney function
  • History of life-threatening Nephrotic Syndrome within 1 year before Screening
  • Diagnosis of anti- phospholipase A2 receptor (PLA2R) negative membranous nephropathy (MN) or anti-PLA2R positive MN but Screening serum anti-PLA2R \< 20 RU/mL or kidney disease other than PMN
  • History of kidney transplant or planned kidney transplant or dialysis during the Treatment Period
  • History of other solid organ (heart, lung, small bowel, pancreas, or liver) or bone marrow transplant; or planned transplant during the Treatment Period
  • History or presence of any co-morbidities
  • History of intolerance or to ACEi or ARB
  • Initiation or dose adjustment of SGLT2i within 12 weeks prior to randomization or planned adjustment of GSLT2i dose throughout the treatment period.
  • Use of traditional Chinese medicines or Chinese proprietary medicines with systemic properties within 6 months prior to screening.
  • Use of MRA, or ERA within 12 weeks prior to randomization and throughout the study period

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    ALXN1920

    Participants will receive ALXN1920 subcutaneous (SC) and background treatment of ACE/ARB and Rituximab.

    Drug: ALXN1920

  • Experimental
    Placebo

    Participants will receive placebo subcutaneous (SC) and background treatment of ACE/ARB and Rituximab.

    Drug: Placebo

Interventions

  • DrugALXN1920

    Participants will receive ALXN1920 SC infusion.

  • DrugPlacebo

    Participants will receive Placebo SC infusion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Proteinuria Based on 24-hour UPCR at Week 26

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in Proteinuria Based on 24-hour UPCR at week 12

    Time frame: Baseline and week 12

  2. Change From Baseline in Proteinuria Based on Spot UPCR at Week 12 and week 26

    Time frame: Baseline, Week 12 and Week 26

  3. Change From Baseline in Serum Albumin at Week 12 and week 26

    Time frame: Baseline, week 12 and Week 26

  4. Change From Baseline in Anti-phospholipase A2 Receptor (anti-PLA2R) Antibody Level at Week 12 and week 26

    Time frame: Baseline, week 12 and week 26

  5. Change From Baseline in Peripheral CD19+ B Cell Count at Week 4, Week 8, Week 12 and Week 26

    Time frame: Baseline, Weeks 4, 8, 12 and 26

  6. Change From Baseline biomarker level at Week 12 and 26

    Time frame: Baseline and Weeks 12 and 26

07

Study locations

35 of 40 sites recruiting
  • Research Site
    Loma Linda, California 92354, United States
    Recruiting
  • Research Site
    San Diego, California 92123, United States
    Recruiting
  • Research Site
    Minneapolis, Minnesota 55435, United States
    Recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Buenos Aires, 1425, Argentina
    Recruiting
  • Research Site
    CABA, C1425HFA, Argentina
    Recruiting
  • Research Site
    Ciudad de Buenos Aires, 1280, Argentina
    Recruiting
  • Research Site
    La Plata, B1902COS, Argentina
    Not yet recruiting
  • Research Site
    Rosario, 2000, Argentina
    Recruiting
  • Research Site
    Santa Fe, S3000EOZ, Argentina
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Santa Fe, S3000, Argentina
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Gosford, 2250, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Parkville, 3050, Australia
    Recruiting
  • Research Site
    Southport, 4222, Australia
    Recruiting
  • Research Site
    Recife, 50670-901, Brazil
    Recruiting
  • Research Site
    Salvador, 40301-155, Brazil
    Recruiting
  • Research Site
    São Paulo, 04038-002, Brazil
    Recruiting
  • Research Site
    São Paulo, 05403-000, Brazil
    Recruiting
  • Research Site
    Baotou, 014010, China
    Recruiting
  • Research Site
    Beijing, 100034, China
    Recruiting
  • Research Site
    Guangzhou, 510080, China
    Recruiting
  • Research Site
    Shenzhen, 518036, China
    Recruiting
  • Research Site
    Créteil, 94010, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Nice, 06000, France
    Recruiting
  • Research Site
    Toulouse, 31059, France
    Recruiting
  • Research Site
    Milan, 20122, Italy
    Recruiting
  • Research Site
    Ranica, 24020, Italy
    Recruiting
  • Research Site
    Torrette, 60126, Italy
    Recruiting
  • Research Site
    Barcelona, 08025, Spain
    Recruiting
  • Research Site
    Madrid, 28007, Spain
    Recruiting
  • Research Site
    Seville, 41013, Spain
    Recruiting
  • Research Site
    Toledo, 45007, Spain
    Recruiting
  • Research Site
    Kaohsiung City, 81362, Taiwan
    Recruiting
  • Research Site
    Taichung, 40705, Taiwan
    Recruiting
  • Research Site
    Taoyuan, 333, Taiwan
    Recruiting
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
    Recruiting
  • Research Site
    Leicester, LE5 4PW, United Kingdom
    Recruiting
  • Research Site
    London, SE5 9RJ, United Kingdom
    Recruiting
  • Research Site
    Salford, M6 8HD, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jul 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 5, 2025
StartActual
Sep 19, 2025
Primary completionEst.
Jul 2, 2027
CompletionEst.
Jul 9, 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07157787
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Sep 19, 2025
Primary completion
Jul 2, 2027 (estimated)
Completion
Jul 9, 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Alexion Pharmaceuticals, Inc. (Sponsor)
Contact
clinicaltrials@alexion.com
1-855-752-2356

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion